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BACKGROUND: The CDC recommends routine volun-
tary HIV testing of all patients 13-64 years of age.
Despite this recommendation, HIV testing rates are low
even among those at identifiable risk, and many
patients do not return to receive their results.
OBJECTIVE: To examine the costs and benefits of
strategies to improve HIV testing and receipt of results.
DESIGN: Cost-effectiveness analysis based on a Markov
model. Acceptance of testing, return rates, and related
costs were derived from a randomized trial of 251
patients; long-term costs and health outcomes were
derived from the literature.
SETTING/TARGET POPULATION:Primary-care patients
with unknown HIV status.
INTERVENTIONS: Comparison of three intervention
models for HIV counseling and testing: Model A =
traditional HIV counseling and testing; Model B =
nurse-initiated routine screening with traditional HIV
testing and counseling; Model C = nurse-initiated rou-
tine screening with rapid HIV testing and streamlined
counseling.
MAIN MEASURES: Life-years, quality-adjusted life-years
(QALYs), costs and incremental cost-effectiveness.
KEY RESULTS: Withoutconsiderationofthebenefitfrom
reduced HIV transmission, Model A resulted in per-
patient lifetime discounted costs of $48,650 and benefits
of 16.271 QALYs. Model B increased lifetime costs by $53
and benefits by 0.0013 QALYs (corresponding to 0.48
quality-adjusted life days). Model C cost $66 more than
Model A with an increase of 0.0018 QALYs (0.66 quality-
adjusted life days) and an incremental cost-effectiveness
of $36,390/QALY. When we included the benefit from
reduced HIV transmission, Model C cost $10,660/QALY
relative to Model A. The cost-effectiveness of Model C was
robust in sensitivity analyses.
CONCLUSIONS: In a primary-care population, nurse-
initiated routine screening with rapid HIV testing and
streamlined counseling increased rates of testing and
receipt of test results and was cost-effective compared
with traditional HIV testing strategies.
KEY WORDS: HIV; cost-benefit analysis; highly active antiretroviral
therapy; transmission; nurse-initiated HIV screening; HIV rapid testing;
Streamlined counseling.
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INTRODUCTION
Efforts to identify people early in the course of HIV infection in
the United States have had limited success. Approximately
half of patients are identified with HIV only when they have
advanced disease.
1,2 Recent CDC estimates indicate 38.3% of
patients had received an AIDS diagnosis within a year of their
HIV diagnosis; another 6.7% received an AIDS diagnosis from
1 to 3 years after their HIV diagnosis.
3 The Centers for Disease
Control and Prevention (CDC) estimates that approximately
232,000 people who have HIV in the US are not aware they are
infected.
4 Approximately 21% of infected individuals across the
US are unaware of their HIV status;
5 the transmission rate
from HIV-infected individuals unaware of their infection is up
to 3.5 times higher that from individuals who are aware of their
infection.
6 The toll from this lack of awareness is high: over
14,000 new infections per year are caused by people who do
not know they have HIV.
7,8
Based on these findings, and on studies that indicate that
risk-based screening fails to identify many people with HIV, the
CDC now recommends that screening for HIV should be
performed routinely for all patients between the ages 13-64
in health-care settings.
1 A recent guidance statement from the
American College of Physicians also recommends routine
screening.
9 Routine screening for HIV is cost-effective, even
with prevalence as low as 0.05% to 0.1%,
10–12 which likely
includes most health-care settings. Screening is also cost-
effective for patients up to the age of 75, if it is performed with
streamlined counseling.
13
Despite the strong rationale for screening, there are many
potential barriers to implementation of routine testing for HIV,
and even patients at high-risk often are not tested.
7,14–16 We
report here the cost-effectiveness of three alternative strategies
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556for implementing HIV testing that were evaluated previously in
a randomized control trial.
17 The three strategies are tradi-
tional HIV counseling and testing, nurse-initiated routine
screening with traditional counseling and testing, and nurse-
initiated routine screening with streamlined counseling and
rapid HIV testing. The cost-effectiveness of these strategies is
important because the randomized trial demonstrated that
nurse-initiated routine screening with streamlined counseling
and rapid HIV testing results in substantially higher testing
rates, higher rates of receiving test results, and equivalent
sexual risk behaviors and HIV knowledge post-intervention,
when compared to traditional HIV counseling and testing.
17
METHODS
We estimated the health and economic effects of strategies to
increase HIV testing rates and receipt of results using a decision
model. We followed the recommendations of the Panel on Cost-
Effectiveness in Health and Medicine for performing and report-
ing a cost-effectiveness analysis.
18 We used the perspective of a
perfect insurer,
19 which uses costs to the insurer and patient,
and corresponds to what most studies term a societal perspec-
tive. Both costs and benefits were discounted at a 3% annual
rate,
20 and patients were followed for their lifetime.
We adapted a Markov model
21,22 developed to assess the cost-
effectiveness of voluntary HIV screening in health-care set-
tings
12,13 using Decision Maker software. Calibration and
validation of the decision model and its outputs occurred as an
iterative process throughout its development. HIV natural
history and treatment effects were compared to published
estimates, and our assumptions were modified as needed to
calibrate to these data.
11,23–25
The model tracked a cohort of patients over their lifetime.
Patients were offered HIV testing and received their results
through one of three methods: (1) traditional HIV testing and
counseling (Model A), (2) nurse-initiated screening with tradi-
tional HIV testing and counseling (Model B), or (3) nurse-
initiated screening with rapid HIV testing and streamlined
counseling (Model C) (Fig. 1). For each strategy, we replicated
the rates of HIV testing and receipt of results observed in the
RCT.
17 Each month, the model assessed the patients’ HIV
status, whether their HIV was identified, the clinical course of
HIV disease, the costs and consequences of HIV transmission
and of highly active antiretroviral therapy (HAART) for patients
identified with HIV and eligible for treatment. Estimates for HIV
natural history, treatment, transmission of HIV and quality-of-
life were derived from high-quality published literature and
expert clinical judgment. Our methods have been described
previously
12,13 (Appendix available online)
Figure 1. Schematic representation of decision model. The square node at the left represents the initial decision to initiate HIV testing through
a physician-based or nurse-based strategy, and then whether traditional or streamlined counseling is performed. Patients in each strategy
can then accept or refuse HIV screening. Once screened for HIV, patients could receive their test results or not. All patients regardless of their
testing status then enter the Markov model (gray box). In all strategies, patients who do not receive screening through their initial interaction
with the physician or nurse may be screened at a later date through symptom-based case finding. We assumed that the frequency with
which case finding occurred was 80% annually below a CD4 count of 50 cells per cubic millimeter, linearly related to the CD4 count between
50 and 350 cells per cubic millimeter, and not relevant (0%) with a CD4 count of more than 350 cells per cubic millimeter, when patients were
assumed to be asymptomatic. Model A = traditional HIV counseling and testing; Model B = nurse-initiated screening with traditional HIV
testing and counseling; Model C = nurse-initiated screening with rapid HIV testing and streamlined counseling.
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Our cohort was modeled to reflect the patients in the RCT.
17 The
trial included 251 patients from two Department of Veterans
Affairs (VA) sites in Southern California. The clinics were both
primary-care clinics with urgent-care components. One was a
large, university-affiliated hospital, and the other was an urban
outpatient clinic serving many indigent and homeless veterans.
Patients were eligible for inclusion in the RCT if they met all of
the following criteria: (1) aged 18–65 years, (2) unaware of their
HIV status, (3) had not received an HIV test in the past year, (4)
had an appointment with a provider in the target clinic that day,
(5) were proficient in English and (6) were competent to consent
to the study.
17
Patients in the trial were on average 49.7 years old, 32%
White, 43% African American, essentially all men, 9.6% were
men who have sex with men, and the prevalence of undiagnosed
HIV in the population was 0.398% (Table 1).
17 Age- and sex-
specific incidence of future HIV in the patient population was
based on previous models.
4,8,26–28
Table 1. Input Variables and Sources
Variable Base case value Range Distribution
a Source
Demographics
Age, years 49.7 40–60 Normal
17
Prevalence of undiagnosed HIV, % 0.398 0.1–5 Beta
17
Men who have sex with men, % 9.6 0–25
17
HIV test characteristics, %
Sensitivity of traditional testing 99.6 98–99.9 Beta
12
Specificity of traditional testing 99.9994 99–100 Beta
12
Sensitivity of rapid testing 99.6 98–100 Beta http://www.fda.gov/cber/faq/oraqckfaq.htm
Specificity of rapid testing 99.9994 96–100 Discrete Assumed to be equal to traditional testing,
47
Screening strategies
Probability of having an HIV test, %
Model A (traditional HIV counseling
and testing)
41.0 30.2–51.8 Beta
17
Model B (nurse-initiated screening
with traditional counseling)
84.5 76.7–92.3 Beta
17
Model C (nurse-initiated screening
with streamlined counseling and
rapid testing)
89.3 82.5–96.1 Beta
17
Probability of receiving HIV test result
(given test negative), %
Model A 35.3 18.9–51.7 Beta
17
Model B 36.6 25.2–48.0 Beta
17
Model C 89.3 82.1–96.5 Beta
17
Probability of receiving HIV test result
(given test positive), %
Model A 90 30–100 Beta Estimate and range based on
7,15,48
Model B 90 30–100 Beta Estimate and range based on
7,15,48
Model C 100 80–100 Beta Estimate and range based on
7,15,48
Costs, $
HIV screening, negative test, $
Conventional screening 12.41 9.30–15.50 CMS reimbursement rates for the VA for
CPT 86701 HIV-1 EIA
Rapid test screening 11.45 8.50–14.50 Abbott Laboratories
HIV screening, positive test, $
Conventional screening 51.87 38.90–64.84 CMS reimbursement rates for the VA for
CPT 86701 HIV-1 EIA and second EIA
and CPT 86689 HIV-1 Western blot
Rapid test screening 50.91 38.18–63.64 CMS reimbursement rates for the VA for CPT
86701 HIV-1 EIA and second EIA and CPT
86689 HIV-1 Western blot incorporating
rapid test screening cost
Pre-test counseling, $
Conventional counseling 10.16 6.77–13.55 Gamma Based on 15 min (range 10–20 min) for an HIV
counselor at a average salary of $81,307
Streamlined counseling 5.00 0.30–9.69 Gamma Based on 7.38 min (standard deviation
6.9 min) for an HIV counselor at a average
salary of $81,307
Post-test counseling for negative
results, $
1.36 0.68–6.78 Based on 2 min (range 1–10 min) for an
HIV counselor at an average salary of $81,307.
Same cost for post-test counseling of negative
results regardless of testing type
Post-test counseling for positive
results, $
13.55 20.33–40.65 Based on 20 min (range 10–60 min) for an HIV
counselor at an average salary of
$81,307. Same cost for post-test counseling
of positive results regardless of testing type
aIndicates the distribution used in the probabilistic sensitivity analysis
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The strategies in our analysis reflected those of the RCT. In
strategy Model A, patients were encouraged by a nurse to
discuss their need for a HIV-screening test with their physi-
cian. If the patient and physician agreed on HIV screening, the
test, as well as the pre- and post-test counseling, was based on
standard pretest and posttest counseling performed by a
trained counselor. HIV screening was performed using a HIV-
1 serum enzyme-linked immunosorbent assay (EIA) test and, if
positive, was followed by a repeat HIV-1 EIA test and a HIV-1
Western blot analysis. Per the published literature, we as-
sumed traditional HIV testing had a sensitivity of 99.6% and a
specificity of 99.9994%.
12
In the Model B strategy, the nurse recommended that the
patient get screened for HIV and, if the patient agreed, they
were then referred for traditional counseling/testing.
Model C involved the nurse recommending HIV screening to
the patient. If the patient agreed to testing, then the patient was
screened using an oral swab and the OraQuick® rapid screening
test (OraSure Technologies, Inc, Bethlehem PA). Sensitivity of
rapid HIV testing was based on OraQuick data and assumed to
be 99.6%. The pre-test counseling was performed using a
streamlined procedure
1 that took approximately 7 min. Post-test
counseling and follow-up of positive rapid HIV tests were
performed in all strategies by a trained HIV counselor.
The trial indicated that traditional HIV counseling and testing
(Model A) resulted in lower rates of testing (41%) and receipt of
results given testing (35.3%) than did the nurse-initiated
strategies (Models B and C), as shown in Table 1. The most
successful strategy was Model C, nurse-initiated routine screen-
ing with streamlined counseling and rapid HIV testing, in which
approximately 90% of patients were tested and 90% of those
tested received results (Table 1).
Quality of Life
The model incorporated adjustments for the quality of life
associated with age-specific current health, HIV disease
(asymptomatic HIV, symptomatic HIVand AIDS) and HAART.
12
Utilities measure the patient’s quality of life and were rated on
a scale from 0 to 1, where 0 represents death and 1 ideal
health. We multiplied utilities based on HIV-related health
status and knowledge by age-specific utility weights derived
from the Beaver Dam Health Outcomes Study.
29
Costs
We included the direct costs of medical care associated with
physician and nurse time, HIV testing (initial and confirmatory
tests) and counseling, follow-up and treatment of patients
identified with HIV infection (Table 1). We did not include costs
associated with patient time. Costs of conventional HIV testing
were derived from Centers for Medicare and Medicaid (CMS)
reimbursement rates for the VA, while cost of rapid HIV testing
was estimated from Abbott Laboratories. Costs of conventional
pre-test and post-test counseling were based on the estimated
time needed for a VA-based HIV counselor and using an
average annual salary of $81,300 (Table 1). The time required
for streamlined counseling prior to HIV testing was determined
through a time-costing analysis in the RCT (average time = 7.4
min). Costs of HIV treatment and follow-up were based on our
earlier analysis.
12,13 We included age-specific medical expen-
ditures unrelated to HIV care based on data from the Bureau
of Labor Statistics (http://www.bls.gov/cex/csxann05.pdf). All
costs were updated to 2007 dollars.
30
Sensitivity Analyses
We performed one-way and multi-way sensitivity analyses to
account for important model assumptions and uncertainties.
For variables derived from the randomized trial, ranges
represent the 95% confidence intervals reported in the trial.
For HIV natural history and clinical variables, our ranges for
sensitivity analyses represent our judgment of the variation
likely to be encountered in clinical practice on the basis of both
the literature and discussion with experts. We varied costs in
sensitivity analyses based on the standard deviation observed
in the time-costing analysis, expert clinical judgment or
assuming costs increased/decreased by 25%. A probabilistic
sensitivity analysis was also performed, and its assumptions
and findings are described in the Appendix available online.
RESULTS
We estimated the increase in life expectancy and quality-
adjusted life expectancy that resulted from identification and
treatment of HIV through the nurse-initiated screening (Mod-
els B and C) compared with traditional HIV counseling and
testing. For an HIV-infected patient (49.7 years), Model B
increased life expectancy by 0.64 years or 0.47 QALYs
compared with Model A. If the nurse-initiated strategy includ-
ed rapid testing and streamlined counseling (Model C), life
expectancy was increased by 0.87 years or 0.63 QALYs
compared to Model A (Fig. 2).
Model A resulted in the lowest costs and effectiveness
(Table 2 and Fig. 3). Model B was more effective and costly, and
ModelCwasthemosteffectiveandmostcostly(Table2).Note that
lifetime costs in Table 2 include all direct medical costs for
screening, counseling and treatment, as well as age-specific
medical costs unrelated to HIV care, and that our estimated HIV
prevalence of 0.398% was based on the trial results. Although
Model B is more effective than Model A, Model C has a more
favorable cost-effectiveness ratio than does Model B; thus Model
B is eliminated by extended dominance (Table 2). Extended
dominance occurs when a more expensive strategy has a lower
cost-effectiveness ratio than a competing (dominated) strategy; in
this case, the more expensive alternative would always be
preferable, since the outcome gain more than compensates for
the cost. The additional gains in health benefit from Model C cost
$36,390/QALY,withoutconsiderationofthebenefitfromreduced
transmission. Including these benefits resulted in a more favor-
able cost-effectiveness ratio of $10,660/QALY (Table 2,F i g .3).
Sensitivity Analyses
If the prevalence of unidentified HIV was lowered from 0.398%
to 0.05%, the cost-effectiveness of Model C compared with
Model A was less favorable at $58,900/QALY (Fig. 4) without
the benefits from reduced transmission; the cost-effectiveness
was $25,300/QALY with the benefit from reduced transmis-
sion included. Including the benefits to partners, Model C cost
less than $75,000/QALY as long as the prevalence of uniden-
tified HIV was greater than 0.01%.
559 Sanders et al.: Cost-Effectiveness of HIV Testing Strategies JGIMThe benefits of Model C to patients are two-fold (i.e., the
probability of a patient receiving an HIV test is increased, and
given that HIV testing occurs, patients were more likely to
receive these results). In sensitivity analyses we explored the
effect of these two elements. If 89.3% of patients received their
test results through rapid-testing and streamlined counseling
(base-case estimates), then even if the HIV test acceptance rate
was reduced to 40%, the cost-effectiveness ratio of Model C
increased from the base case estimate of $10,660/QALYonly to
$13,240/QALY.
Sensitivity analyses with other model variables (Table 1) did
not change our results substantially. If the specificity of rapid
testing was reduced to 96.1% and all positive tests were
confirmed by an EIA, Western blot and viral load tests, Model
C remained cost-effective at $17,400/QALY.
DISCUSSION
We evaluated the cost-effectiveness of three strategies for
implementing routine HIV screening. We used testing and
counseling costs and receipt of test result outcomes from a
previously performed randomized trial as inputs to a model-
based analysis that estimated lifetime costs and health out-
comes.This approachenabled us toassess the cost-effectiveness
of these strategies by including both short- and long-term costs
and health outcomes, in accordance with guidelines for the
conduct of cost-effectiveness analyses.
18
Ourmainfindingisthatnurse-initiatedroutinescreeningwith
streamlined counseling and rapid HIV testing is cost-effective
relative to traditional HIV counseling and testing. The increased
effectiveness and the resulting cost-effectiveness occur because
this strategy resulted in much higher rates of receipt of test
results. This strategy, at $36,390/QALY gained, met convention-
al thresholds for cost-effectiveness relative to Model A. When we
considered the benefit to sexual partners from reduced trans-
mission, rapid testing with streamlined counseling was even
more favorable and cost $10,660/QALY gained.
Although the CDC now recommends routine HIV screening in
all health-care settings, implementation of screening remains a
Table 2. Health and Economic Outcomes
Outcome Benefits to partners excluded Benefits to partners included
Model A Model B Model C Model A Model B Model C
Patients tested, % 41.0 84.5 89.3 41.0 84.5 89.3
Tested patients who receive results, % 35.3 36.6 89.3 35.3 36.6 89.3
Lifetime cost, $ 48,650 48,710 48,720 49,040 49,060 49,070
Incr. cost, $ 53 13 27 4
LY, years 18.8330 18.8348 18.8355 18.8153 18.8178 18.8187
Incr. LY, years (life days)
a 0.0018 (0.65) 0.0007 (0.25) 0.0025 (0.91) 0.0009 (0.34)
Incremental cost-effectiveness, $/LY Extended dominance
b 26,710
c Extended dominance
b 9,240
c
QALY, years 16.2714 16.2727 16.2732 16.2530 16.2551 16.2559
Incr. QALY, years (days)
a 0.0013 (0.48) 0.0005 (0.19) 0.0021 (0.77) 0.0008 (0.29)
Incremental cost-effectiveness, $/QALY Extended dominance
b 36,390
c Extended dominance
b 10,660
c
aOne life year (LY) = 365 life days; one quality-adjusted life year (QALY) = 365 quality-adjusted life days
bExtended dominance = extended dominance occurs when a more expensive strategy has a more favorable cost-effectiveness ratio than a less expensive
strategy; in this case, the more expensive alternative would always be preferable, since the outcome gain more than compensates for the cost
cBecause the Model B strategy is eliminated through extended dominance, the incremental cost-effectiveness ratios listed compare the Model C strategy
directly to the Model A strategy. Model A = traditional counseling and testing; Model B = nurse-initiated screening with traditional counseling, Model C =
nurse-initiated screening with streamlined counseling and rapid testing
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Figure 2. Effect of nurse-initiated screening strategies on life
expectancy of HIV-infected patients. The effect on (a) undis-
counted life expectancy and (b) undiscounted quality-adjusted
life expectancy of using nurse-initiated testing for HIV infection, as
compared with traditional counseling and testing (Model A). The
solid line demonstrates the benefit to HIV-infected patients from
incorporating streamlined counseling and rapid testing into the
nurse-initiated strategy (Model C), while the dashed line represents
nurse-initiated testing with traditional counseling (Model B).
560 Sanders et al.: Cost-Effectiveness of HIV Testing Strategies JGIMchallenge, and few health-care systems have integrated screen-
ing into routine care. We believe that three elements of Model C
contributed to the success of this strategy. First, the use of non-
physician providers, in our case, nurses, substantially increased
the rate of testing. This finding is consistent with a substantial
body of literature that supports the use of non-physician
providers for preventive care.
31–36 For example, a systematic
review of 81 studies found that the most potent type of
intervention to increase preventive services was organizational
change, including designation of non-physician staff to perform
specific prevention activities.
36 Use of non-physician providers
has the additional potential advantage of reducing per-person
test costs by substitution of less expensive personnel. In our
trial, aggregate costs were higher for the strategies that used
nurse-initiated screening (Models B and C), but the increase in
costs was related to the higher rates of testing, which offset the
reduction in time and personnel costs.
The second important component of this strategy was
streamlined counseling. With traditional testing and counseling,
counseling costs are substantial, and for patients with negative
tests are approximately 15 times higher than the cost of the HIV
test itself.
12 In the randomized trial, traditional pre-test counsel-
ing required 20 min on average. In contrast, streamlined pre-
test counseling took 7 min, which resulted in a reduction in
counseling costs of 65%. In the trial, there were no differences in
HIV knowledge or in sexual risk behavior between the tradition-
al or streamlined counseling groups.
17 This result is consistent
with that of the RESPECT-2 randomized trial of over 1,600
patients that compared rapid HIV testing and counseling in one
visit to standard testing and counseling over two visits.
37
However, the counseling for rapid testing in RESPECT-2
required 30 min and was likely both more costly and more
intensive than our streamlined counseling. In addition, in post-
hoc subgroup analyses in RESPECT-2, one time counseling
appeared modestly less effective in men, suggesting that further
evaluation of streamlined counseling is needed.
The third important component of this strategy was rapid
testing. Rapid testing enabled patients to receive test results in
approximately 20 min, whereas traditional testing required two
visits and results were not available for 1 to 2 weeks. In our trial,
the test costs were similar for rapid versus traditional testing.
Our results about receipt of testing are consistent with a
number of studies that indicate that rapid testing substantially
increases the receipt of results
16,38–41 a n di sa c c e p t a b l et o
patients.
42,43 Recent studies have also indicated the potential
economic benefits of rapid testing strategies.
44,45
Although the convenience of rapid testing is an important
advantage, continued evaluation of the accuracy of rapid testing
is necessary. In our trial, we had only one positive result, which
was a true positive; thus, the false-positive rate was 0. However,
a trial of testing in emergency department with rigorous quality
control found a false-positive rate of approximately 3.1%.
46
Patients should be counseled that positive rapid tests require
confirmation.
Our trial was performed at two VA primary-care clinics in
southern California, which raises the question of whether the
results will be applicable in other settings. Although the rates of
acceptance and receipt of result are likely to vary across
settings, we believe the three components of our most effective
strategy (initiation of testing by non-physician providers, use of
streamlined counseling and rapid testing) are likely to be useful
in other settings. Rapid testing has been evaluated in many
environments, and use of non-physician providers has been
studied in many prevention domains, as noted previously. The
use of streamlined counseling addresses an important challenge
to providers who have many competing demands on their time.
Our study has several limitations. As noted, our trial was
performed in VA primary and urgent care settings, which have
different patient populations than many primary or urgent care
practices. In our trial, about 17% of patients approached for
participation agreed to enter the study. Because this was a
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Figure 3. Health and economic outcomes of testing and counsel-
ing strategies. (a) Benefits to partners excluded; (b) benefits to
partners included.
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Figure 4. Sensitivity analysis of the effect of unidentified HIV
prevalence on the incremental cost-effectiveness of the nurse-
initiated rapid testing and streamlined counseling strategy (Model
C) compared with traditional counseling and testing (Model A).
The solid line includes the costs and benefits to partners, while the
dashed line excludes these effects.
561 Sanders et al.: Cost-Effectiveness of HIV Testing Strategies JGIMresearch study, informed consent was required, and the require-
ments for follow-up may have discouraged some patients from
participating. Thus, the implications for implementation of
screening outside a trial are not known. The cost-effectiveness
of screening however would not be affected by the participation
rate since a change in participation would increase/decrease
costs and benefits proportionally. In addition, the VA populations
we studied do not reflect the distributions or the risk groups in
some other populations or settings. Because our results may not
be generalizable to non-VA setting,furtherstudy in other settings
would be helpful. In addition, longer term assessment of
effectiveness of streamlined counseling would be useful; our
follow-up did not extend beyond 4 weeks. Finally, our cost-
effectiveness analysis assumed that identified patients would
have accesstoHIVcare, whichistrue inthe VA,but may nothold
in some settings. The benefit from screening would be less than
we estimated if patients did not have full access to care.
We believe our study is relevant to primary care settings.
Although the need for informed consent in our study precludes
completely reproducing routine opt-out screening in a medical
setting, we did offer testing routinely to all patients, which is in
essence the CDC recommendation. We note, however, that there
are potential barriers to implementation of nurse-based screen-
ing with rapid testing (Model C), which include lack of nursing
time, prioritization of other tasks over HIV testing, lack of
familiarity with rapid test procedures among nursing staff and
the logistics of lengthening clinic encounters because patients
must wait for test results. The importance of these barriers is
likely to vary by clinical setting.
The current CDC guidelines recommend routine screening in
healthsettings, a substantialchangein policyfromtargeted risk-
based screening. How best to implement routine screening is
uncertain. We found that nurse-initiated screening with stream-
lined counseling and rapid testing (Model C) was an effective
strategy to increase testing and receipt of results, and is cost-
effective by conventionally accepted thresholds when compared
with traditional counseling/testing. Our study suggests that this
strategy has substantial promise as an approach for integrating
routine HIV screening into the practice of primary care.
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